Table 1.
Characteristics for stage IIIB/IV NSCLC patients and proportion with receipt of any chemotherapy
| Patient Characteristics | Percent of Patients with Characteristic N= 6,614 |
Percent of patients who received chemotherapy with characteristic N = 3,612 |
Effects of patient characteristics on receipt of any first-line chemotherapy within 120 days of diagnosis |
||
|---|---|---|---|---|---|
| OR | 95% CI | P | |||
| Age at diagnosis, years | |||||
| < 55 | 12.9 | 73.4 | Ref | ||
| 55 – 64 | 25.0 | 65.8 | 0.70 | 0.580 to 0.837 | 0.0001 |
| 65 – 69 | 18.0 | 61.4 | 0.58 | 0.475 to 0.697 | < .0001 |
| 70 – 74 | 17.5 | 49.1 | 0.35 | 0.289 to 0.423 | < .0001 |
| 75 – 79 | 14.2 | 43.0 | 0.27 | 0.224 to 0.333 | < .0001 |
| 80 + | 12.4 | 23.9 | 0.11 | 0.091 to 0.142 | < .0001 |
| Age at diagnosis, years | |||||
| < 65 | 37.8 | 68.4 | Ref | ||
| 65 + | 62.2 | 46.2 | 0.40 | 0.358 to 0.441 | < .0001 |
| Gender | |||||
| Female | 47.4 | 54.5 | Ref | ||
| Male | 52.6 | 54.7 | 1.01 | 0.917 to 1.114 | 0.8265 |
| Race Ethnicity | |||||
| White | 75.5 | 53.4 | Ref | ||
| Hispanic | 6.1 | 58.3 | 1.22 | 0.994 to 1.500 | 0.0571 |
| Black | 7.5 | 56.4 | 1.13 | 0.936 to 1.358 | 0.2066 |
| Asian/Pacific Islander | 8.6 | 62.5 | 1.45 | 1.215 to 1.736 | < .0001 |
| Other race | 2.3 | 49.7 | 0.86 | 0.624 to 1.188 | 0.3638 |
| % college educated (census tract quintile) |
|||||
| 1 (lowest) | 20.5 | 51.8 | Ref | ||
| 2 | 19.6 | 52.5 | 1.03 | 0.882 to 1.196 | 0.7337 |
| 3 | 20.2 | 53.7 | 1.08 | 0.926 to 1.254 | 0.3319 |
| 4 | 20.3 | 56.5 | 1.21 | 1.039 to 1.407 | 0.0141 |
| 5 (highest) | 19.4 | 58.7 | 1.32 | 1.135 to 1.545 | 0.0003 |
| Median income (census tract quintile) |
|||||
| 1 (lowest) | 20.8 | 51.5 | Ref | ||
| 2 | 19.6 | 50.4 | 0.96 | 0.823 to 1.115 | 0.5818 |
| 3 | 20.5 | 53.9 | 1.10 | 0.948 to 1.281 | 0.2049 |
| 4 | 19.5 | 56.3 | 1.22 | 1.043 to 1.416 | 0.0123 |
| 5 (highest) | 19.7 | 61.1 | 1.48 | 1.269 to 1.725 | < .0001 |
| Modified Charlson comorbidity score |
|||||
| 0 | 44.3 | 58.7 | Ref | ||
| 1 | 25.6 | 56.7 | 0.92 | 0.818 to 1.042 | 0.1981 |
| 2 | 9.8 | 53.7 | 0.82 | 0.689 to 0.969 | 0.0205 |
| 3+ | 20.3 | 43.5 | 0.54 | 0.475 to 0.617 | < .0001 |
| AJCC Stage at Diagnosis | |||||
| III | 28.1 | 57.9 | Ref | ||
| IV | 71.9 | 53.3 | 0.83 | 0.747 to 0.927 | 0.0009 |
| Tumor Grade | |||||
| Well-moderately differentiated |
12.9 | 54.8 | Ref | ||
| Poorly differentiated/undifferenti ated |
26.8 | 53.4 | 0.95 | 0.802 to 1.113 | 0.4968 |
| Unknown | 60.2 | 55.1 | 1.01 | 0.874 to 1.176 | 0.8601 |
| Year of Diagnosis | |||||
| 2000 | 11.5 | 51.1 | Ref | ||
| 2001 | 12.2 | 49.6 | 0.94 | 0.771 to 1.146 | 0.5388 |
| 2002 | 12.3 | 49.6 | 0.94 | 0.771 to 1.146 | 0.5390 |
| 2003 | 12.7 | 55.5 | 1.19 | 0.981 to 1.454 | 0.0776 |
| 2004 | 13.1 | 54.7 | 1.15 | 0.949 to 1.402 | 0.1524 |
| 2005 | 13.1 | 58.4 | 1.34 | 1.104 to 1.634 | 0.0032 |
| 2006 | 12.6 | 59.0 | 1.38 | 1.131 to 1.680 | 0.0015 |
| 2007 | 12.5 | 58.2 | 1.33 | 1.092 to 1.624 | 0.0046 |
| HMO | |||||
| A | 56.6 | Ref | |||
| B | 43.7 | 0.59 | 0.508 to 0.694 | < .0001 | |
| C | 49.6 | 0.75 | 0.628 to 0.905 | 0.0025 | |
| D | 56.2 | 0.98 | 0.832 to 1.159 | 0.8313 | |